Home › Metastatic Cancer › NCT04085029

Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Age ≥ 18 years of age
* Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment
* Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s)
* Patient must sign study-specific informed consent

Exclusion Criteria:

• None

About the study

The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.

Sponsor: Duke University · Participants: 300 · Started: Sep 26, 2019

Contact the study team

• Clinical Trials Office · Phone: (919) 668 3726

Official record on ClinicalTrials.gov — NCT04085029

Locations in the U.S.

Conditions

• Metastatic Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.